Vancive Medical Technologies, an Avery Dennison business, and Eloquest Healthcare Inc. have partnered to develop an innovative post-operative dressing that contains an antimicrobial agent called chlorhexidine gluconate (CHG). The antimicrobial properties of CHG inhibit microbial growth within the dressing.

CHG is extremely difficult to incorporate in an absorbent adhesive dressing, making the development of the BeneHold CHG platform a significant technical accomplishment for Vancive. The Eloquest Healthcare ReliaTect Post-Op Dressings with CHG are the first to combine CHG in an absorbent, transparent and waterproof design.

“ReliaTect post-operative dressings are a natural fit for our BeneHold CHG platform, and the needs of patients and clinicians,” said Kirsten Newquist, general manager for Vancive Medical Technologies. “We look forward to further expanding our CHG technology to many more applications.”

ReliaTect is available in small and large sizes with a transparent window for surgical site visualization, and a nonwoven border that facilitates dressing application and provides additional securement during wear. The dressings comfortably adhere to the skin, absorb fluids and protect the site from external contaminants.

ReliaTect Post-Op Dressings with CHG are now commercially available from Eloquest Healthcare in the United States. The device received 510(k) clearance from the FDA in March and is now available nationwide. Eloquest Healthcare is the exclusive distributor of the dressings in the United States and Canada.